The Molecular Pathology of Schizophrenia – Focus on Histone and DNA Modifications

doi:10.1016/j.brainresbull.2009.08.018

Brain Res Bull. Author manuscript; available in PMC 2011 September 30.

Published in final edited form as:

Brain Res Bull. 2010 September 30; 83(3-4): 103–107.

Published online 2009 September 1. doi: 10.1016/j.brainresbull.2009.08.018

PMCID: PMC2963192

NIHMSID: NIHMS242234

The Molecular Pathology of Schizophrenia – Focus on Histone and DNA Modifications

Schahram Akbarian

Schahram Akbarian, Brudnick Neuropsychiatric Research Institute, Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA 01604, Phone 508 8562674, Fax 508 8562627;

Schahram Akbarian: Schahram.akbarian/at/umassmed.edu

The publisher's final edited version of this article is available at Brain Res Bull

See other articles in PMC that cite the published article.

Publisher's Disclaimer

Abstract

Dysfunction of cerebral cortex and other brain regions in schizophrenia is often accompanied by dysregulated expression of numerous genes. However, the underlying genetic risk architecture remains unclear for a large majority of cases. Therefore, the study of epigenetic regulators of gene expression, including covalent modifications of DNA and nucleosome core histones, offers an attractive alternative to further explore the molecular pathology of schizophrenia beyond the level of RNA quantification. Several studies reported alterations in DNA cytosine methylation and histone methylation at specific genes and promoters in postmortem brain of subjects with schizophrenia, often in conjunction with changes in levels of the corresponding RNAs. While evidence for such “epigenetic dysregulation” is increasing, many of the reported alterations await independent replication. Interestingly, studies across the lifespan indicate that DNA and histone methylation markings are developmentally regulated in human cerebral cortex, suggesting that at least some of the epigenetic changes in the brain of adult subjects with schizophrenia reflect disordered neurodevelopment.

Introduction

Schizophrenia is a complex disorder with a concordance rate of less than 70% in monozygotic twins and non-Mendelian inheritance patterns [1]. While the list of copy number variations, microdeletions and polymorphisms associated with genetic risk for schizophrenia is steadily increasing, straightforward genetic causes are still lacking for a large majority of affected individuals[2–6]. In this context, it comes as no surprise that disease models have been put forward that ascribe an important role for ‘epigenetic’ factors to the pathophysiology of schizophrenia[1, 7]. The term ‘epigenetic’ often relates to phenotypes and mechanisms that are the result (or cause) of heritable changes in gene expression and function without any alterations of the DNA sequence [8, 9]. More recently, however, ‘epigenetic’ is applied more broadly and at least in the fields of neuroscience and translational medicine, the term often is mentioned in studies focused on chromatin structure and function in dividing and even in postmitotic cells, including neurons[10–12].

Understanding the molecular architecture of chromatin in normal and diseased brain is thought to be important for maladies such as schizophrenia which typically lack a defining cellular pathology but often are associated with alterations in levels of RNAs encoding a wide range of transcripts involved in inhibitory or excitatory neurotransmission, myelination and metabolism, among others[12, 13]. Because the methylation of DNA at sites of CpG dinucleotides and a wide range of post-translational histone modifications at gene promoters (discussed in detail further below) are involved in the regulation of transcription, these ‘epigenetic’ markings are often studied in schizophrenia postmortem brain in conjunction with quantification of the corresponding RNA molecules[14–16]. The typical working hypothesis implies that a change in promoter DNA methylation or histone modification is a potential indicator for altered gene expression activity at that locus, which in turn leads to an alteration in the level of the corresponding RNA. From this point of view, chromatin assays and the study of epigenetic markings are a most welcome addendum to the toolbox of the postmortem brain researcher because these methods, when combined with more traditional approaches such as the quantification of mRNA and protein, could provide insight into the mechanisms of gene expression during normal brain development and aging, as well as potential alterations in neuropsychiatric disease, including schizophrenia[12, 13].

Several recent excellent reviews summarize our state of knowledge on epigenetic regulation in psychiatric disorders, with the majority of studies published to date primarily focused on preclinical models[10, 17–20]. The purpose of this review will be to provide an overview of the chromatin markings that to date were studied in brain of subjects with schizophrenia, including the potential implications for the neurobiology of the disease, and to discuss current limitations and challenges the field needs to overcome.

Chromatin markings reported to be altered in schizophrenia brain

DNA methylation

In vertebrates, the methylation of cytosine residues at CpG dinucleotides within annotated gene sequences is loosely associated with gene expression activity [21, 22]. However, within regulatory sequences surrounding transcription start sites and proximal promoters, DNA methylation is often (but not always) thought to mediate, or reflect, transcriptional inhibition[21, 22]. To date, most studies exploring DNA methylation changes in schizophrenia postmortem brain were focused on the cerebral cortex, primarily its prefrontal areas. A number of pioneering studies reported various degrees of aberrant CpG hyper- or hypomethylation in regulatory sequences of promoters and genes invoked in the cortical dysfunction of schizophrenia, including the glycoprotein REELIN[14, 15], catechyl-O-methyltransferase (COMT)[23], and SOX10, encoding a transcription factor important for myelination and oligodendrocyte function[24]. It is encouraging that these disease-related hyper(hypo)methylation changes were associated with decreased (increased) levels of the corresponding RNA, thereby reiterating the expected function of CpG methylation around transcription start sites. On the other hand, as discussed further below, at least for the REELIN and COMT genes, the disease-related DNA methylation changes could not be replicated in independent studies[25, 26].

Recently, Petronis’ group reported the outcome of the first comprehensive DNA methylation study on the frontal lobe of (for postmortem standards) comparatively large cohorts of 35 schizophrenia, 35 bipolar and 35 control subjects, using an array-based platform that covered CpG enriched sequences positioned at the 5′ end and the promoters of nearly 8000 annotated genes. That study identified altogether approximately 100 loci that –in a surprisingly gender-specific fashion—were affected by a DNA methylation change in the schizophrenia and bipolar cohorts, covering a wide range of gene functions, including glutamatergic and GABAergic neurotransmission and neurodevelopment [25]. The number of loci showing, in comparison to controls, hyper- vs. hypomethylation, was roughly equal, which makes it very unlikely that schizophrenia is associated with a generalized drift towards increased (or decreased) DNA methylation in brain. A similar conclusion was reached by an earlier study on the temporal cortex of schizophrenia, reporting no significant DNA methylation changes for the entire set of 50 genes examined[27]. Notably, for each of the DNA methylation studies reporting positive findings, the overall magnitude of the disease-related changes, in comparison to controls, were surprisingly subtle. For example, in the Mill et al study, disease-related DNA methylation levels even for one of the most significantly changed genes (WDR18) were reported as 17% vs. 25%[25]. While it is difficult, even for single copy genes, to extrapolate the percentages of methylated DNA extracted from a tissue homogenate to the number of cell nuclei affected, the evidence so far would support the view that many of the DNA methylation changes associated with schizophrenia are likely to involve only a small subset of cells residing in the cerebral cortex.

Furthermore, the observation that many of the DNA methylation-related changes in schizophrenia are sex-specific[25] will require additional follow-up studies. Sex steroids may play a role, and there is ample evidence that estrogen-regulated signaling pathways are linked to epigenetic regulation of chromatin, including DNA and histone methylation [1, 30, 31].

Histone modifications

There are four core histone proteins (H2A, H2B, H3, H4) which comprise an octamer around which 146 bp of genomic DNA are wrapped around; this elementary unit of chromatin fibers is known as the nucleosome. In addition, linker histones, including H1, provide a protein backbone for internucleosomal DNA[32–34]. There is a complex set of posttranslational modifications of specific histone residues located primarily at the N-terminal tail of the core histones. Examples include lysine acetylation and methylation, arginine methylation, serine phosphorylation and also the ubiquitinylation and SUMOlyation of some lysine residues[35, 36]. Several of these modifications are thought to be regulated by transcriptional activity, or are involved in epigenetic control of gene expression[37]. For example, lysine acetylation defines chromatin at sites of actual or potential gene expression, while the small molecule modifier, SUMO, is generally associated with transcriptional inhibition[35]. To date, there is only little or no information on the majority of histone modifications in the context of schizophrenia. A study quantifying histone modifications in bulk chromatin from prefrontal cortex reported increased methylation of the histone H3-arginine 17 (H3-methyl-R17) residue in a subset of schizophrenia cases that showed robust deficits in metabolic gene expression[38]. Because the H3-methyl-R17 mark is predominantly expressed in neuronal nuclei[38], one could speculate that some cases with schizophrenia are affected by more generalized changes in certain types of chromatin modifications in neurons and perhaps also in other cells. The latter hypothesis receives further support by other reports describing altered histone acetylation in immunoblot assays from peripheral blood lymphocytes of subjects diagnosed with schizophrenia[39, 40]. These more generalized molecular alterations of chromatin in schizophrenia are of interest, and in case of the peripheral blood cells worth to be pursued as potential biomarkers for treatment response[39]. However, it remains to be explored how these more generalized alterations in chromatin modifications relate to the pathophysiology of psychosis.

However, histone modifications can be monitored at specific genomic loci via chromatin immunoprecipitation (ChIP), a technique that fortunately is feasible in postmortem tissue[41–43]. Changes in histone acetylation or methylation in chromatin surrounding disease-related genes were reported for neuropsychiatric conditions, including Friedreich’s Ataxia [44]. To date, however, few studies have explored histone modification changes at sites of specific genes in schizophrenia, using either nucleated peripheral blood cells [40] or postmortem brain tissue [16, 45, 46]as input material. For the latter, preference was given to the study of lysine methylation which apparently is less affected by tissue autolysis and other postmortem confounds, at least when compared to acetylation[38, 41]. The study of lysine methylation is also advantageous given that this type of modification is a key component of the complex regulation of chromatin structure and function (including gene expression), whereby the specific position of the modified lysine residue within the histone protein, and even the numbers of (methyl) groups added to the residue, reflect distinct chromatin states differentiating transcriptionally active (“open”) and silenced or repressed loci[12, 35, 47]. For example, coding and non-coding sequences transcribed by the RNA polymerase II complex are typically defined by sharp peaks of trimethylated H3K4 in nucleosomes positioned around transcription start sites and a more broad distribution of trimethylated H3K36, or dimethylated H3K79, along the transcribed region[48–50]. In contrast, mono-methylated H3K4 defines enhancer sequences potentially further removed from transcription start sites[51]. Furthermore, tri-methylated H3K9, H3K27 and H4K20 are associated with repressive chromatin, while at least in human cells monomethylated H3K9 and H4K20 correlate with gene expression levels[52].

Focusing on the distribution of trimethyl-H3K4 and –H3K27, two chromatin marks differentiating between open and repressive chromatin, respectively, Huang et al. observed that a the prefrontal cortex of a subset of subjects with schizophrenia show, in comparison to matched controls, a shift from the H3K4me3 to the H3K27me3 mark in chromatin surrounding the transcription start site of GAD1, encoding 67 KD glutamic acid decarboxylase GABA synthesis enzyme[16]. This observation is of interest given that deficits in GAD67 RNA are considered to be among the most frequently replicated findings in schizophrenia postmortem brain[53], potentially affecting widespread portions of the cerebral cortex, the hippocampus and other areas of forebrain, and even the cerebellar cortex[54–59]. Alterations in GAD67 RNA may also affect cases diagnosed with bipolar disorder and autism[58, 60]. Indeed, the shift from H3K4 to H3K27 methylation at the GAD1 gene in the schizophrenia cases of Huang et al. was accompanied by a deficit in GAD1(GAD67) RNA, in comparison to the matched control[16]. Furthermore, these GAD1-associated alterations in prefrontal chromatin of subjects with schizophrenia were influenced by single nucleotide polymorphisms surrounding the 5′ end of GAD1 previously associated with genetic risk for childhood-onset schizophrenia and other disease, and accelerated loss of cortical gray matter[61–63]. While underlying molecular mechanisms remain to be explored, these findings nonetheless provide some of the first examples how genetic and epigenetic factors could interact and contribute to dysregulated gene expression and eventually, cortical dysfunction and psychosis.

Reproducibility of epigenetic alterations in schizophrenia postmortem brain

Given that, to date, only few studies explored chromatin modifications in schizophrenia postmortem brain, it is difficult to predict whether or not these approaches will contribute to a critical advancement of our knowledge about the mechanisms of disease. As one might expect from an epigenetic marking, recent studies suggest that DNA methylation patterns show, on a genome-wide scale, considerable heterogeneity between individuals, with larger differences between dizygotic as compared to monozygotic twins [64]. Furthermore, the similarities in DNA methylation and histone acetylation patterns among monozygotic twin pairs tend to diminish with age [65]. Given this apparent variability in chromatin markings between individuals, which only increases during the course of aging, it comes as no surprise that to date, the field still awaits independent replication for the reported alterations in schizophrenia postmortem studies. For example, DNA methylation analysis for the REELIN promoter (encoding a glycoprotein essential for orderly brain development and neuronal connectivity) reported either no change [25, 26] in the cerebral cortex of schizophrenics, or identified aberrant hypermethylation at different portions of the gene [14, 15, 66]. Likewise, DNA hypomethylation and increased gene expression for COMT (encoding a key enzyme for catecholamine metabolism) was reported in one study[23] while another group reported no methylation changes for the same gene[25]. Besides of interindividual differences, numerous factors could have contributed to these disparate findings. Importantly, the activity of DNA methyltransferases (the enzymes which methylate DNA) and DNA CpG methylation in a variety of tissues, including CNS, are sensitive to the social environment [67, 68], ischemia[69], environmental toxins[70–72], nicotine[73, 74] alcohol[75], psychostimulants[76, 77], and antipsychotic drugs [25, 78, 79]. It is likely that these factors also play a role in shaping DNA methylation patterns in the human brain, thus further contributing to sample variability in postmortem studies.

Cellular specificity of epigenetic markings

To date, most assays designed to detect and quantify DNA methylation and histone modifications require an input material between 10³-10⁸ nuclei, and this lack of cellular resolution poses a challenge because brain tissue is comprised of an extremely heterogeneous mixture of different cell types. To date, many studies exploring epigenetic dysregulation of gene expression in schizophrenia utilized tissue homogenates for their DNA and histone modification assays, while the gene(s)-of-interest often are expressed only in a select subpopulation of neurons or other cells [14–16, 23–27, 80]. Some of these changes, such as the hypermethylation of the REELIN promoter DNA in cortical layer I of subjects with schizophrenia[15, 81, 82], or the shift from open chromatin-associated (H3-trimethyl-K4) to repressive histone methylation (H3-trimethylK27) at the GAD1 gene promoter could indicate an epigenetic defect in the population of inhibitory interneurons[16]. This is a very attractive working hypothesis that could potentially explain the observed deficits in the corresponding REELIN and GAD1(GAD67) RNAs[83]. A more conclusive test of this hypothesis will await the development of technologies that allow the efficient sorting of GABAergic neuron chromatin directly from postmortem tissue. To this end, some progress has been made. For example, it is possible to purify, immunotag (with anti-NeuN antibody) and sort efficiently 10^{7 -} 10⁸ neuronal and non-neuronal nuclei from less than 1 gram of postmortem cerebral cortex in a single day, thereby enabling separate processing of neuronal and non-neuronal chromatin [84, 85]. These approaches should be, in principle, also applicable to selected subpopulations of neurons and other cell types. As an alternative, it could be feasible to sort chromatin from tissue homogenates with a set of anti-methyl-histone antibodies that differentiate between open chromatin at sites of actual or potential gene expression, and repressive chromatin, and then assay DNA methylation and other types of modifications separately for these different fractions. This approach was used to show that DNA methylation alterations at the GAD1 promoter in schizophrenia selectively affect the fraction of repressive chromatin [45].

Implications for the neurobiology of schizophrenia

As discussed above, the study of DNA and histone modifications at defined promoter sequences in schizophrenia postmortem brain is attractive because this approach could potentially uncover epigenetic mechanisms of dysregulated gene expression in that disorder. However, presently it remains an open question whether some of the above mentioned disease-related promoter DNA and histone methylation changes reflect indeed long-lasting and sustained defects in the regulation of gene expression.

Notably, the reported histone methylation changes in prefrontal GAD1 chromatin of schizophrenia subjects [16]are also of interest from the viewpoint of neurodevelopment. There is evidence that H3K4 methylation is progressively upregulated in human prefrontal cortex at a select set of GABAergic gene promoters (GAD1/GAD2/NPY/SST) during the transitions from the fetal period to childhood and then to adulthood[16]. This extended course of chromatin regulation during the first two decades of life was paralleled by similar increases on the RNA level[16]. Taken together, these findings imply that chromatin remodeling and transcriptional mechanisms involved in the prefrontal dysfunction of schizophrenia also play a role during normal development. Whether the GAD1 chromatin alterations in schizophrenia indeed reflect disordered neurodevelopment, or a type of pathophysiology occurring later in life, remains to be determined in future studies.

From a broader perspective, evidence is emerging that epigenetic markings are highly regulated particularly during late prenatal and early postnatal human brain development. For example, when DNA methylation changes were assayed at 50 gene promoters across the lifespan in human temporal cortex, more than one half of this select set of genes showed age-related methylation changes, which were particularly pronounced during the transition from the fetal period and early childhood years to later stages of development[27]. Likewise, maturation of cerebellar cortex was associated with histone methylation changes in chromatin surrounding glutamate receptor gene chromatin[42]. Future studies that map epigenetic markings on a comprehensive, genome-wide scale during normal human brain development will be necessary in order to find out whether or not these developmental changes are representative for a significant portion of the genome and whether or not schizophrenia-related risk loci and genes show age-related changes. Given the emerging link between childhood adversity, epigenetic dysregulation of gene expression and adult psychopathology[86, 87], it is not unlikely that a neurodevelopmental approach will also advance our current understanding of chromatin-associated alterations in brains of subjects with schizophrenia.

Acknowledgments

Research conducted by the author is supported by grants from the National Institutes of Health and the Staglin Family Music Festival Schizophrenia Research Award/NARSAD.

Footnotes

The author reports no conflicts of interest.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Kaminsky Z, Wang SC, Petronis A. Complex disease, gender and epigenetics. Ann Med. 2006;38(8):530–44. [PubMed]

2. Delisi LE. Searching for the true genetic vulnerability for schizophrenia. Genome Med. 2009;1(1):14. [PMC free article] [PubMed]

3. Smith M. The year in human and medical genetics. Highlights of 2007–2008. Ann N Y Acad Sci. 2009;1151:1–21. [PubMed]

4. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455(7210):237–41. [PubMed]

5. Bertolino A, Blasi G. The genetics of Schizophrenia. Neuroscience. 2009

6. Lupski JR. Schizophrenia: Incriminating genomic evidence. Nature. 2008;455(7210):178–9. [PubMed]

7. Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics. 2005;5(3):149–60. [PubMed]

8. Jablonka E, Lamb MJ. The changing concept of epigenetics. Ann N Y Acad Sci. 2002;981:82–96. [PubMed]

9. Berger SL, et al. An operational definition of epigenetics. Genes Dev. 2009;23(7):781–3. [PubMed]

10. Tsankova N, et al. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 2007;8(5):355–67. [PubMed]

11. Jiang Y, et al. Epigenetics in the nervous system. J Neurosci. 2008;28(46):11753–9. [PubMed]

12. Akbarian S, Huang HS. Epigenetic regulation in human brain-focus on histone lysine methylation. Biol Psychiatry. 2009;65(3):198–203. [PMC free article] [PubMed]

13. Connor CM, Akbarian S. DNA methylation changes in schizophrenia and bipolar disorder. Epigenetics. 2008;3(2):55–8. [PubMed]

14. Abdolmaleky HM, et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005;134B(1):60–6. [PubMed]

15. Grayson DR, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci U S A. 2005;102(26):9341–6. [PubMed]

16. Huang HS, et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci. 2007;27(42):11254–62. [PubMed]

17. Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol. 2008;8(1):57–64. [PMC free article] [PubMed]

18. Sweatt JD. Experience-dependent epigenetic modifications in the central nervous system. Biol Psychiatry. 2009;65(3):191–7. [PMC free article] [PubMed]

19. Monteggia LM, Kavalali ET. Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. Biol Psychiatry. 2009;65(3):204–10. [PMC free article] [PubMed]

20. Levenson JM, Sweatt JD. Epigenetic mechanisms in memory formation. Nat Rev Neurosci. 2005;6(2):108–18. [PubMed]

21. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet. 2008;9(6):465–76. [PubMed]

22. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31(2):89–97. [PubMed]

23. Abdolmaleky HM, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet. 2006;15(21):3132–45. [PMC free article] [PubMed]

24. Iwamoto K, et al. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci. 2005;25(22):5376–81. [PubMed]

25. Mill J, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet. 2008;82(3):696–711. [PubMed]

26. Tochigi M, et al. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry. 2008;63(5):530–3. [PubMed]

27. Siegmund KD, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS ONE. 2007;2(9):e895. [PMC free article] [PubMed]

28. Berman KF, et al. Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci U S A. 1997;94(16):8836–41. [PubMed]

29. Dreher JC, et al. Menstrual cycle phase modulates reward-related neural function in women. Proc Natl Acad Sci U S A. 2007;104(7):2465–70. [PubMed]

30. Garcia-Bassets I, et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell. 2007;128(3):505–18. [PMC free article] [PubMed]

31. Perillo B, et al. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science. 2008;319(5860):202–6. [PubMed]

32. Quina AS, Buschbeck M, Di Croce L. Chromatin structure and epigenetics. Biochem Pharmacol. 2006;72(11):1563–9. [PubMed]

33. Chakravarthy S, et al. Structure and dynamic properties of nucleosome core particles. FEBS Lett. 2005;579(4):895–8. [PubMed]

34. Robinson PJ, Rhodes D. Structure of the ‘30 nm’ chromatin fibre: a key role for the linker histone. Curr Opin Struct Biol. 2006;16(3):336–43. [PubMed]

35. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447(7143):407–12. [PubMed]

36. Rando OJ. Global patterns of histone modifications. Curr Opin Genet Dev. 2007;17(2):94–9. [PubMed]

37. Allis CD, et al. New nomenclature for chromatin-modifying enzymes. Cell. 2007;131(4):633–6. [PubMed]

38. Akbarian S, et al. Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry. 2005;62(8):829–40. [PubMed]

39. Gavin DP, et al. Reduced baseline acetylated histone 3 levels, and a blunted response to HDAC inhibition in lymphocyte cultures from schizophrenia subjects. Schizophr Res. 2008;103(1–3):330–2. [PubMed]

40. Gavin DP, et al. Histone deacetylase inhibitors and candidate gene expression: An in vivo and in vitro approach to studying chromatin remodeling in a clinical population. J Psychiatr Res. 2009 [PubMed]

41. Huang HS, et al. Chromatin immunoprecipitation in postmortem brain. J Neurosci Methods. 2006;156(1–2):284–92. [PubMed]

42. Stadler F, et al. Histone methylation at gene promoters is associated with developmental regulation and region-specific expression of ionotropic and metabotropic glutamate receptors in human brain. J Neurochem. 2005;94(2):324–36. [PubMed]

43. Matevossian A, Akbarian S. A chromatin assay for human brain tissue. J Vis Exp. 2008;(13) [PubMed]

44. Al-Mahdawi S, et al. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet. 2008;17(5):735–46. [PubMed]

45. Huang HS, Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS ONE. 2007;2(8):e809. [PMC free article] [PubMed]

46. Mellios N, et al. Molecular Determinants of Dysregulated GABAergic Gene Expression in the Prefrontal Cortex of Subjects with Schizophrenia. Biol Psychiatry. 2008 [PubMed]

47. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev. 2002;12(2):198–209. [PubMed]

48. Guttman M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7. [PMC free article] [PubMed]

49. Klose RJ, et al. Demethylation of histone H3K36 and H3K9 by Rph1: a vestige of an H3K9 methylation system in Saccharomyces cerevisiae? Mol Cell Biol. 2007;27(11):3951–61. [PMC free article] [PubMed]

50. Seila AC, et al. Divergent transcription from active promoters. Science. 2008;322(5909):1849–51. [PMC free article] [PubMed]

51. Heintzman ND, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007;39(3):311–8. [PubMed]

52. Barski A, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823–37. [PubMed]

53. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005;6(4):312–24. [PubMed]

54. Hashimoto T, et al. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry. 2008;165(4):479–89. [PMC free article] [PubMed]

55. Guidotti A, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry. 2000;57(11):1061–9. [PubMed]

56. Fatemi SH, et al. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res. 2005;72(2–3):109–22. [PubMed]

57. Bullock WM, et al. Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am J Psychiatry. 2008;165(12):1594–603. [PubMed]

58. Benes FM, et al. Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolars. Proc Natl Acad Sci U S A. 2008;105(52):20935–40. [PubMed]

59. Dracheva S, et al. GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. J Neurosci Res. 2004;76(4):581–92. [PubMed]

60. Akbarian S, Huang HS. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev. 2006;52(2):293–304. [PubMed]

61. Addington AM, et al. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry. 2005;10(6):581–8. [PubMed]

62. Lundorf MD, et al. Mutational screening and association study of glutamate decarboxylase 1 as a candidate susceptibility gene for bipolar affective disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2005;135B(1):94–101. [PubMed]

63. Rapoport JL, et al. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry. 2005;10(5):434–49. [PubMed]

64. Kaminsky ZA, et al. DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet. 2009;41(2):240–5. [PubMed]

65. Fraga MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102(30):10604–9. [PubMed]

66. Abdolmaleky HM, et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005;134(1):60–6. [PubMed]

67. Weaver IC, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7(8):847–54. [PubMed]

68. Rampon C, et al. Effects of environmental enrichment on gene expression in the brain. Proc Natl Acad Sci U S A. 2000;97(23):12880–4. [PubMed]

69. Endres M, et al. DNA methyltransferase contributes to delayed ischemic brain injury. J Neurosci. 2000;20(9):3175–81. [PubMed]

70. Bollati V, et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res. 2007;67(3):876–80. [PubMed]

71. Desaulniers D, et al. Comparisons of brain, uterus, and liver mRNA expression for cytochrome p450s, DNA methyltransferase-1, and catechol-o-methyltransferase in prepubertal female Sprague-Dawley rats exposed to a mixture of aryl hydrocarbon receptor agonists. Toxicol Sci. 2005;86(1):175–84. [PubMed]

72. Salnikow K, Zhitkovich A. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem Res Toxicol. 2008;21(1):28–44. [PMC free article] [PubMed]

73. Satta R, et al. Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons. Proc Natl Acad Sci U S A. 2008;105(42):16356–61. [PubMed]

74. Satta R, et al. Stimulation of brain nicotinic acetylcholine receptors (nAChRs) decreases DNA methyltransferase 1 (DNMT1) expression in cortical and hippocampal GABAergic neurons of Swiss albino mice. Society for Neuroscience Abstract. 2007

75. Marutha Ravindran CR, Ticku MK. Changes in methylation pattern of NMDA receptor NR2B gene in cortical neurons after chronic ethanol treatment in mice. Brain Res Mol Brain Res. 2004;121(1–2):19–27. [PubMed]

76. Numachi Y, et al. Methamphetamine alters expression of DNA methyltransferase 1 mRNA in rat brain. Neurosci Lett. 2007;414(3):213–7. [PubMed]

77. Numachi Y, et al. Psychostimulant alters expression of DNA methyltransferase mRNA in the rat brain. Ann N Y Acad Sci. 2004;1025:102–9. [PubMed]

78. Cheng MC, et al. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsychopharmacol. 2008;11(2):207–16. [PubMed]

79. Shimabukuro M, et al. Haloperidol treatment induces tissue- and sex-specific changes in DNA methylation: a control study using rats. Behav Brain Funct. 2006;2:37. [PMC free article] [PubMed]

80. Tamura Y, et al. Epigenetic aberration of the human REELIN gene in psychiatric disorders. Mol Psychiatry. 2007;12(6):519, 593–600. [PubMed]

81. Veldic M, et al. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proc Natl Acad Sci U S A. 2004;101(1):348–53. [PubMed]

82. Veldic M, et al. In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci U S A. 2005;102(6):2152–7. [PubMed]

83. Guidotti A, et al. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci. 2009;30(2):55–60. [PubMed]

84. Jiang Y, et al. Isolation of neuronal chromatin from brain tissue. BMC Neurosci. 2008;9:42. [PMC free article] [PubMed]

85. Matevossian A, Akbarian S. Neuronal nuclei isolation from human postmortem brain tissue. J Vis Exp. 2008;(20) [PubMed]

86. McGowan PO, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009;12(3):342–8. [PMC free article] [PubMed]

87. McGowan PO, et al. Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain. PLoS ONE. 2008;3(5):e2085. [PMC free article] [PubMed]